HUMAN RESTRICTIN AND NUCLEIC ACID SEQUENCES

Abstract: Human restrictin proteins and nucleic acid sequences encoding them are provided. Antibodies which recognize human restrictin in human brain are disclosed. In the human brain, restrictin occurs as two major polypeptides of 180 and 160 kD located in fiber tracts. These polypeptides are similar to those seen in rat brain. Surprisingly, restrictin has also been found in the peripheral nerves of rats and humans. The antibodies also detect a 170 kD polypeptide in MATRIGEL<TM>, an extracellular matrix product of rat EHS sarcoma cells widely used as a tissue culture substrate. Monoclonal antibodies to human restrictin and assays using the human restrictin protein, antibodies and DNA sequences are also provided.

Description: HUMAN RESTRICTIN AND NUCLEIC ACID SEQUENCES FIELD OF THE INVENTION The present invention relates to extracellular matrix molecules and nucleic acid sequences encoding them. BACKGROUND OF THE INVENTION The adherence of cells to each other and to the extracellular matrix, as well as the cellular signals transduced as a consequence of such binding, are of fundamental importance to the development and maintenance of body form and function A number of molecules mediating cell adhesion have been identified and characterized at the molecular level both in vertebrates and in invertebrates Many cell surface cell adhesion molecules (CAMs) are of three major types: 1 ) members of the immunoglobulin supergene family, which mediate calcium independent adhesion, 2) cadherins, which mediate calcium-dependent adhesion and are important structural components of adherence junctions, and 3) integrins, a family of heterodimeric proteins which can facilitate adhesion of cells both to each other and to the extracellular matrix CAMs may have multiple ligands. They can mediate adhesion by the interaction of a CAM on one cell with the identical CAM on another cell (homophilic binding), or they can mediate adhesion by interacting with different CAMs or extracellular matrix molecules (heterophilic binding) For example, contactin, a member of the immunoglobulin gene superfamily, can undergo homophilic binding or can bind heterophilically to other cell surface molecules such as the L I antigen or to extracellular matrix molecules of the tenascin family One extracellular matrix ligand for contactin is janusin, which is a member of the tenascin-R family. Janusin is closely related to tenascin in its patterns of epidermal growth factor, fibronectin type III and fibrinogen-like domains In rodents, it is synthesized by StlBSπiUH SHEET (Mllf 26) oligodendrocytes and subpopulations of neurons at late developmental stages in the central nervous system It can promote cell adhesion or anti-adhesion, depending on the neural cell type with which it interacts, promoting neurite outgrowth of some neural cell types and inhibiting neurite outgrowth from other neuronal populations The repulsive response of neurons to janusin may be mediated by contactin Janusin has been identified in rodents (A Faissner, et al 1990 J. Neurochem. 54 1004-1015) and the rat gene has been cloned (B Fuss, et al 1991. J. Neurosa. Res. 29 299-307) and sequenced (B Fuss, et al 1993 J. Cell Bwl. 120 1237-1249) The chicken homolog of janusin, referred to as restrictin, has also been identified and characterized (U Norenberg, et al 1992 Neuron 8 849-863) SUMMARY OF THE INVENTION Prior to the present invention, no human homolog of janu si /restrict in had been identified and it was not previously known if such a homolog existed A human homolog of rat janusin has now been found, and the complete cDNA sequence encoding it has been determined Antisera were prepared against a fragment of the human restrictin protein expressed in bacteria These antibodies detect the immunogen, high molecular weight polypeptides in human brain, and cross react with several animal species In the human brain, restrictin occurs as two major polypeptides of 180 and 160 kD located in fiber tracts These polypeptides are similar in size to those seen in rat brain Surprisingly, restrictin has also been found in the peripheral nerves of rats and humans The antibodies also detect a 170 kD polypeptide in MATRIGEL, an extracellular matrix product of rat EHS sarcoma cells widely used as a tissue culture substrate Monoclonal antibodies to human restrictin and assays using the human restrictin protein, antibodies and DNA sequences are also provided DESCRIPTION OF THE DRAWINGS Fig 1 illustrates the cloning process used to obtain the human restrictin cDNA sequence DETAILED DESCRIPTION OF THE INVENTION cDNAs encoding human restrictin were cloned from human brain polyA-t- RNA using the reverse transcriptase polymerase chain reaction (RT-PCR) with primers based on the rat janusin gene sequence RT-PCR was performed on rat and human (adult and fetal, Clontech) brain polyA+ RNA using the one-step protocol described by Goblet et al ( 1989 Nucl Acids Res. 17:2144). PolyA+ RNA (1 μg) and 300 ng of each primer (see below) in 66 μl DEPC water were incubated at 65°C for 15 min. and cooled on ice. Thirty-three μl of 3X RT-PCR reagent mix (3X PCR buffer, 150 miM KC1, 30 mM Tris-HCl pH 8.3, 4.5 mM MgCl 2 , 0.3% gelatin, 500 μM dNTPs, 200 U M-MLV reverse transcriptase, 4 U rRNAsin (Promega, Madison, WI), 2.5 U AMPLITAQ (Perkin-El er Cetus, Norwalk, CT) was added and the reaction was incubated at 37°C for 30 min. The amplification reaction (94°C for 1 min., 50°C for 2 min., and 72°C for 2 min.) was repeated for 40 cycles. The primer pair for amplification was as follows: 5'-ACTGACAGATCTAGAGCC SEQ ID NO: 1 (corresponding to nucleotides 2375-2392 in rat ) 5'-GGTGGTCGATAGGATACT SEQ ID NO 2 (corresponding to nucleotides 2856-2839 in rat) A major 480 bp amplification product was obtained from rat RNA, which was subcloned and sequenced, confirming that this product corresponded to rat janusin A minor 290 bp product was also obtained in rat. An amplification product of the appropriate size (480 bp) was also generated from human adult brain RNA This product was subcloned and sequenced directly (Mihovilovic, 1989). Amplification of fetal RNA produced only a 290 bp amplification product which was subsequently found not to be human restrictin The 480 bp human amplification product (206/207N) was used as a probe on Northern blots of multiple regions of human brain (Clontech) The radiolabeled probe was prepared using a random primer labeling kit (BRL, Gaithersburg. MD) with purification over NICK columns (Pharmacia, Piscataway, NJ). Blots were reprobed with a human beta-actin probe (Clontech) to determine the relative amounts and integrity of RNA in each sample The probe hybridized to a single approximately 12 Kb nucleic acid sequence in amygdala, caudate nucleus, corpus collusum, hippocampus, hypothalamus, substantia nigra, subthalamic nuclei and thalamus The restrictin cDNA clones described below were also used as probes on northern blots of human fetal tissues The approximately 12 Kb restrictin mRNA seen in adult brain was also detected in fetal brain, but was absent from fetal heart, lung, liver and kidney This illustrates the tissue specificity of restrictin Two commercially available lambda human cDNA libraries were screened as recommended by the manufacturer using 206/207N as a probe to identify additional clones for determination of the sequence of the full-length human restrictin gene (Fig 1 ) Initial SlflSTITUTE SHEET (RULE 26) screening with 206/207N identified cDNA clones 6-1 and 6-2 A second hybridization screening using a probe from the 5' end of clone 6-1, as illustrated in Fig 1, produced cDNA clones 12 and 15. The upstream end of clone 12 was used in a third library screen to isolate clone 20 Together, these clones encode the entire protein coding region of human restrictin (Fig. 1). The lambda cDNA inserts of these clones were either 1) PCR amplified using lambda gtlO EcoRI forward and reverse primers for direct sequencing as described above (Mihovilovic, 1989), or 2) subcloned into pBLUESCRIPT (SK+) (Stratagene, La Jolla, CA) for sequencing by dye-termination or dye-labeled primer methods (Applied Biosystems, Model 373A, Foster City, CA) Sequencing primers were synthesized on an Applied Biosystems (ABI) Model 380B DNA synthesizer and purified using OPC cartridges (ABI) Sequence alignments, translations, and feature location were performed using IG-Suite software (Intelligenetics, Mountain View, CA) In this manner, the entire 4,724 bp human restπctin cDNA coding sequence was determined by sequencing both strands of the cDNAs (SEQ ID NO:3) The sequence of the full-length restrictin protein (1358 amino acids, SEQ ID NO 4) was deduced from the cDNA sequence The human restrictin protein shows structural similarity to other members of the tenascin-R family In particular, human restrictin, like its homologs from rat and chicken, comprises a short amino terminal region followed by heptad repeats, epidermal growth factor-like repeats, nine fibronectin type III repeats and a carboxyl- terminal region homologous to the globular domain of fibrinogen There is no evidence for a hydrophobic membrane spanning region, consistent with restrictin being a secreted, extracellular matrix molecule The human sequence obtained is highly homologous to the rat and chicken sequences at both the DNA (88 and 76%, respectively, within the protein coding region) and at the amino acid level (93 and 72%, respectively) SEQ ID NO 3, a fragment of SEQ ID NO 3, or an equivalent nucleic acid molecule which employs degenerate codons to encode the amino acid sequence of SEQ ID NO 4 or a fragment thereof, may be cloned into an expression vector as is known in the art to produce recombinant human restrictin in transformed or transfected host cells Recombinant human restrictin and recombinant human restrictin fragments provide a convenient source of these molecules for immunization, immunoassays, and use in tissue culture growth substrates To generate antisera to human restrictin, the 206/207N fragment (nucleotides 2686-3 165 of SEQ ID NO.3 with EcoRI cloning sites at both the 5' and 3' ends) was subcloned into the EcoRI site of pGEX-3X (Pharmacia), producing a recombinant human restrictin-glutathione-S-transferase (GST) fusion protein for immunization After transformation of E coli, expression of the fusion protein was induced with IPTG and the soluble material was purified over a glutathione- S Sepharose affinity column The purified material was used to immunize rabbits using __ STπUlΕSfiET(RϋLE26) standard methods. Sera were collected and assayed by immunoblotting against the immunogen and against the 206/207N protein fragment, expressed by subcloning into the pATH expression system (New England BioLabs). The anti-fusion protein antisera recognized both of these antigens on Western blots, but anti-chicken restrictin did not, indicating immunological differences between the human and chicken restrictin proteins To verify the reactivity of the antisera against human proteins, adult brain membranes were prepared and extracted. In brief, postsmortem human brain was Dounce homogenized into 0.32 M sucrose, 5 mM EDTA, 20 mM Tris-HCl (pH 8) containing 1 mM PMSF, 0 5 mM p-chloromercuriphenylsulfonic acid and 5 μg/ml of aprotinin and leupeptin as protease inhibitors. After centrifugation at 500 xg for 30 min to remove nuclei and cellular debris, the supernatant was centrifυged at 80,000 xg to collect the membrane fraction, which was then extracted with 1% sodium deoxycholate in homogenization buffer for 1 5 hr at 4°C The detergent extract was clarified by centrifugation at 100,000 xg and used subsequently for either SDS-PAGE directly or for further purification of a protein fraction bearing the HNK-1 epitope, which may be involved in binding cell adhesion molecules HNK-1 brain fractions were immunoaffinity enriched on anti-Leu7 (Becton Dickinson) coupled to Sepharose Immunoblotting was performed using a PROTOBLOT AP system (Promega) as recommended by the manufacturer with an alkaline phosphatase-conjugated anti-rabbit IgG as the secondary antibody and color development using NBT/BCIP In Western blots, the anti-fusion protein antisera routinely detected two bands of approximately 180 and 160 kD in human brain and in HNK-1 enriched fractions These bands were apparently enriched in the latter The reactivity of the antisera was inhibited in a concentration dependent manner by addition of the GST fusion protein, but not by addition of GST, indicating a specific immune reaction to the human restrictin fragment Western blots of rat, mouse, cow pig and chicken brain extracts demonstrated similar sized bands ( 180 kD and 160 kD) in all cases There were, however. slight mobility shifts, possibly due to species variation in amino acid sequence or to differential glycosylation MATRIGEL (Collaborative Biomedical Products), an extracellular matrix substrate derived from rat EHS sarcoma cells as an in vitro tissue culture growth substrate. was also reactive with the antiserum, revealing a 170 kD polypeptide For immunohistological studies, frozen human or rat tissues were sectioned and fixed using acetone or 4% paraformaldehyde Staining was performed using the VECTA-STAI ELITE ABC system (Vector Laboratories) as recommended Primary anti-fusion protein antisera were used at a 1 1000 dilution Paraffin sections were treated using the microwave antigen retrieval system (U S Patent No 5,244,787) before staining The antisera were SUBSTΠUTE SHEET (R1JLE 26) reactive with frozen sections of human peripheral nerve (peripheral nervous system), rat hippocampus (central nervous system) and human cerebellum (central nervous system) and with paraffin section human pons (central nervous system) In all cases, there were areas of clear positivity as well as areas that were clearly negative For example, in the peripheral nerve experiments, the surrounding, non-neuronal tissue was unstained, and in the central nervous system, there were clearly unstained cells in all areas examined Antibodies according to the invention which recognize human restrictin are useful in methods for detecting the protein in immunoassay systems Polyclonal antisera raised to human restrictin or to protein fragment of human restrictin may be used to detect the restπctin protein in immunoassay methods involving binding between the protein or fragment and the antibodies, e g , ELISAs and immunoblots These conventional immunoassay methods can be readily adapted to employ the antibodies and restrictin protein disclosed herein Alternatively, monoclonal antibodies which recognize the human restrictin protein of the invention may be prepared using methods known in the art, such as that of Kohler and Milstem (1975 Nature 256 495) and used in immunoassays The spleen cells of mice immunized with the human restrictin protein or a fragment thereof are fused with muπne myeloma cells and the resulting hybridomas are screened against the immunogen to select those producing the desired anti- restrictin monoclonal antibody In general, binding between protein and antibody in an immunoassay is detected by inclusion of a detectable label in the reaction which generates a signal The detectable label is usually conjugated to the antibody or protein and may be directly detectable (e g , a dye, radioisotope or fluorochrome) or rendered detectable after further chemical reaction (e g , an enzyme which reacts to produce a colored product, or biotin which may be bound to labeled avidin) Polyclonal and monoclonal antibodies according to the invention may also be used to purify human restrictin from tissues, or to purify restrictin from the tissues of a cross-reacting species by immunoaffinity purification methods, e g , immunoaffinity chromatography This provides a source of natural restrictin for use in immunoassays, as an immunogen, or in tissue culture systems to promote or inhibit neurite outgrowth Ohgonucleotides deπved from the nucleotide sequences encoding human restπctin are useful in nucleic acid hybridization assays for detection of related restrictin nucleotide sequences They may also be used as primers for amplification of restrictin target sequences Oligonucleotide probes for hybridization according to the invention may comprise the complete coding sequence of the human restπctin cDNA or a portion thereof, such as SUBSTITUTE SUET (RULE 26) nucleotides 2686-3165 of SEQ ID NO.3 Primers are generally short portions of the nucleotide sequence which specifically hybridize to restrictin nucleotide sequences, allowing specific amplification One skilled in the art will further recognize that oligonucleotide probes and primers may also be designed which comprise all or a portion of a sequence which is complementary to SEQ ID NO:3. Detection of nucleic acids by hybridization to a probe is known in the art Such methods as Southern blotting. Northern blotting, dot blotting, nucleic acid amplification methods and the like may be readily adapted to detection of nucleotide sequences containing all or part of the human restrictin coding sequence, or to detection of all or part of the restrictin coding sequence of a cross-reacting species This is done using the nucleotide sequence given in SEQ ID NO.3 to design appropriate probes and primers For purposes of the present invention, the terms "encoding" and "coding for" are intended to include nucleic acids which comprise sequences which can be transcribed and/or translated to produce restrictin, or a fragment thereof, including degenerate nucleotide sequences It will also be understood that probes and primers derived from the disclosed nucleotide sequences may also be used to detect fragments of restrictin coding sequences Hybridization of the probe or amplification by the primers may be detected by means of a directly or indirectly detectable label associated with the probe or primer, i e , incorporated into the probe or conjugated to it In general, the same labels useful for labeling antibodies and antigens may be used to label oligonucleotides In addition, it is within the ordinary skill in the art, given the nucleotide sequence of SEQ ID NO.3, to derive the complementary nucleotide sequence, which may also be used to prepare probes and primers and which may be detected by use of probes and primers Further, the present disclosure of SEQ ID NO 3 allows derivation of RNA sequences which are complementary to SEQ ID NO 3 or to the complement of SEQ ID NO 3 Such equivalent RNA sequences may be detected by hybridization or amplification as well The reagents for performing these immunoassays, hybridization assays, and nucleic acid amplification may be conveniently packaged together for sale or use in the form of a kit A kit for immunoassay may contain an antibody which recognizes and binds to restrictin The antibody may be labeled, or a second antibody carrying the label may be included for detection of binding Optionally, any reagent required for performing the assay and detecting the label may be included A kit for hybridization assays or amplification may contain oligonucleotide probes or primers which hybridize to one or more nucleotide sequences contained in SEQ ID NO 3 The probes or primers may be conjugated to a detectable label for detection Optionally, the hybridization or amplification kit may contain any reagents required for performing the hybridization or amplification and detecting the label The foregoing disclosure is intended to illustrate the invention and is not to be construed as limiting its scope as defined by the appended claims. Upon reading the present disclosure, certain equivalents and variations will be apparent to one skilled in the art without exercise of inventive skill. Such equivalents and variations are intended to be included within the scope of the invention. SUBSTITUTE SHffT (RULE 26) SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Reid, Robert A. Ackley, Rhonda L. Hemperly, John J. (ii) TITLE OF INVENTION: HUMAN RESTRICTIN AND NUCLEIC ACID SEQUENCES (iii) NUMBER OF SEQUENCES: 4 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Richard J. Rodrick, Becton Dickinson and Company (B) STREET: 1 Becton Drive (C) CITY: Franklin Lakes (D) STATE: NJ (E) COUNTRY: US (F) ZIP: 07417 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Fugit, Donna R. (B) REGISTRATION NUMBER: 32,135 (C) REFERENCE/DOCKET NUMBER: P-33 1 (2) INFORMATION FOR SEQ ID NO: 1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: ACTGACAGAT CTAGAGCC 18 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear SUBSTTIUIE SHEET RUlf 26 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2 : GGTGGTCGAT AGGATACT 1 (2) INFORMATION FOR SEQ ID NO:3 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4724 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE; cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3 : GAATTCCGGG AGAAGGGGGT CCTCTCTGAC CCAAGGAATT ACCACTAGTG GAGTGAAGCC 60 ACCTGACTTT TTGATCTTAT TTTGGTTGCC TCCTCATTCT CCTTCCACCC GTAGCCCTGA 120 CAGCTTGGGT TTCATTTCTT TCGTGGAGCC TTGTCTCTTC CTCCCAGAAT AGGAGGAAGG 180 GAAGAGAAGG GAAAGAGGAG GGCTCTCTAG GTGAGCGCAT CAGCTGGCTC CAGCCTGAGC 240 AAGCAAGAAT TTTCTTCCCA GGAAGCTCCT CTCGCTCCCC GGCCGCCCAC CCCCAGCCTG 300 GGTGGCTGTA TCGTTTTAAC TGCATAGAGG GCAGGTCTCT TTTGGAATTA GGATTAAAGA 360 AAGTGCAGTA AAGAGAAAGC ATCGAAGACA CCATCACAAA AGATTCCCAC AACTCCATGC 420 TGTGTGCTGC AGGCTGGTCC TGAACCCAGA TCTCTGGCTG AGAGGATGGG GGCAGATGGG 480 GAAACAGTGG TTCTGAAGAA CATGCTCATT GGCGTCAACC TGATCCTTCT GGGCTCCATG 540 ATCAAGCCTT CAGAGTGTCA GCTGGAGGTC ACCACAGAAA GGGTCCAGAG ACAGTCAGTG 600 GAGGAGGAGG GAGGCATTGC CAACTACAAC ACGTCCAGCA AAGAGCAGCC TGTGGTCTTC 660 AACCACGTGT ACAACATTAA CGTGCCCTTG GACAACCTCT GCTCCTCAGG GCTAGAGGCC 720 TCTGCTGAGC AGGAGGTGAG TGCAGAAGAC GAGACTCTGG CAGAGTACAT GGGCCAGACC 780 TCAGACCACG AGAGCCAGGT CACCTTTACA CACAGGATCA ACTTCCCCAA AAAGGCCTGT 840 CCATGTTCCA GTTCAGCCCA GGTGCTGCAG GAGCTGCTGA GCCGGATCGA GATGCTGGAG 900 AGGGAGGTGT CGGTGCTGCG AGACCAGTGC AACGCCAACT GCTGCCAAGA AAGTGCTGCC 960 ACAGGACAAC TGGACTATAT CCCTCACTGC AGTGGCCACG GCAACTTTAG CTTTGAGTCC 1020 TGTGGCTGCA TCTGCAACGA AGGCTGGTTT GGCAAGAATT GCTCGGAGCC CTACTGCCCG 1080 CTGGGTTGCT CCAGCCGGGG GGTGTGTGTG GATGGCCAGT GCATCTGTGA CAGCGAGTAC 1140 AGCGGGGATG ACTGTTCCGA ACTCCGGTGC CCAACAGACT GCAGCTCCCG GGGGCTCTGC 1200 GTGGACGGGG AGTGTGTCTG TGAAGAGCCC TACACTGGCG AGGACTGCAG GGAACTGAGG 1260 TGCCCTGGGG ACTGTTCGGG GAAGGGGAGA TGTGCCACCG GTACCTGTTT ATGCGAGGAG 1320 10 SUBSTITUTE SHEET (RUIf 26) GGCTACGTTG GTGAGGACTG CGGCCAGCGG CAGTGTCTGA ATGCCTGCAG TGGGCGAGGA 1380 CAATGTGAGG AGGGGCTCTG CGTCTGTGAA GAGGGCTACC AGGGCCCTGA CTGCTCAGCA 1440 GTTGCCCCTC CAGAGGACTT GCGAGTGGCT GGTATCAGCG ACAGGTCCAT TGAGCTGGAA 1500 TGGGACGGGC CGATGGCAGT GACGGAATAT GTGATCTCTT ACCAGCCGAC GGCCCTGGGG 1560 GGCCTCCAGC TCCAGCAGCG GGTGCCTGGA GATTGGAGTG GTGTCACCAT CACGGAGCTG 1620 GAGCCAGGTC TCACCTACAA CATCAGCGTC TACGCTGTCA TTAGCAACAT CCTCAGCCTT 1680 CCCATCACTG CCAAGGTGGC CACCCATCTC TCCACTCCTC AAGGGCTACA ATTTAAGACG 1740 ATCACAGAGA CCACCGTGGA GGTGCAGTGG GAGCCCTTCT CATTTTCCTT CGATGGGTGG 1800 GAAATCAGCT TCATTCCAAA GAACAATGAA GGGGGAGTGA TTGCTCAGGT CCCCAGCGAT 1860 GTTACGTCCT TTAACCAGAC AGGACTAAAG CCTGGGGAGG AATACATTGT CAATGTGGTG 1920 GCTCTGAAAG AACAGGCCCG CAGCCCCCCT ACCTCGGCCA GCGTCTCCAC AGTCATTGAC 1980 GGCCCCACGC AGATCCTGGT TCGCGATGTC TCGGACACTG TGGCTTTTGT GGAGTGGATT 2040 CCCCCTCGAG CCAAAGTCGA TTTCATTC T TTGAAATATG GCCTGGTGGG CGGGGAAGGT 2100 GGGAGGACCA CCTTCCGGCT GCAGCCTCCC CTGAGCCAAT ACTCAGTGCA GGCCCTGCGG 2160 CCTGGCTCCC GATACGAGGT GTCAGTCAGT GCCGTCCGAG GGACCAACGA GAGCGATTCT 2220 GCCACCACTC AGTTCACAAC AGAGATCGAT GCCCCCAAGA ACTTGCGAGT TGGTTCTCGC 2280 ACAGCAACCA GCCTTGACCT CGAGTGGGAT AACAGTGAAG CCGAAGTTCA GGAGTACAAG 2340 GTTGTGTACA GCACCCTGGC GGGTGAGCAA TATCATGAGG TACTGGTCCC CAAGGGCATT 2400 GGTCCAACCA CCAGGGCCAC CCTGACAGAT CTGGTACCTG GCACTGAGTA TGGAGTTGGA 2460 ATATCTGCCG TCATGAACTC ACAGCAAAGC GTGCCAGCCA CCATGAATGC CAGGACTGAA 2520 CTTGACAGTC CCCGAGACCT CATGGTGACA GCCTCCTCAG AGACCTCCAT CTCCCTCATC 2580 TGGACCAAGG CCAGTGGCCC CATTGACCAC TACCGAATTA CCTTTACCCC ATCCTCTGGG 2640 ATTGCCTCAG AAGTCACCGT ACCCAAGGAC AGGACCTCAT ACACACTAAC AGATCTAGAG 2700 CCTGGGGCAG AGTACATCAT TTCCGTCACT GCTGAGAGGG GTCGGCAGCA GAGCTTGGAG 2760 TCCACTGTGG ATGCTTTCAC AGGCTTCCGT CCCATCTCTC ATCTGCACTT TTCTCATGTG 2820 ACCTCCTCCA GTGTGAACAT CACTTGGAGT GATCCATCTC CCCCAGCAGA CAGACTCATT 2880 CTTAACTACA GCCCCAGGGA TGAGGAGGAA GAGATGATGG AGGTCTCCCT GGATGCCACC 2940 AAGAGGCATG CTGTCCTGAT GGGCCTGCAA CCAGCCACAG AGTATATTGT GAACCTTGTG 3000 GCTGTCCATG GCACAGTGAC CTCTGAGCCC ATTGTGGGCT CCATCACCAC AGGAATTGAT 3060 CCCCCAAAAG ACATCACAAT TAGCAATGTG ACCAAGGACT CAGTGATGGT CTCCTGGAGC 3120 CCTCCTGTTG CATCTTTCGA TTACTACCGA GTATCATATC GACCCACCCA AGTGGGACGA 3180 CTAGACAGCT CAGTGGTGCC CAACACTGTG ACAGAATTCA CCATCACCAG ACTGAACCCA 3240 11 røSΪU SHUT (RU1E 26) GCTACCGAAT ACGAAATCAG CCTCAACAGC GTGCGGGGCA GGGAGGAAAG CGAGCGCATC 3300 TGTACTCTTG TGCACACAGC CATGGACAAC CCTGTGGATC TGATTGCTAC CAATATCACT 3360 CCAACAGAAG CCCTGCTGCA GTGGAAGGCA CCAGTGGGTG AGGTGGAGAA CTACGTCATT 3 20 GTTCTTACAC ACTTTGCAGT CGCTGGAGAG ACCATCCTTG TTGACGGAGT CAGTGAGGAA 3480 TTTCGGCTTG TTGACCTGCT TCCTAGCACC CACTATACTG CCACCATGTA TGCCACCAAT 3540 GGACCTCTCA CCAGTGGCAC CATCAGCACC AACTTTTCTA CTCTCCTGGA CCCTCCGGCA 3600 AACCTGACAG CCAGTGAAGT CACCAGACAA AGTGCCCTGA TCTCCTGGCA GCCTCCCAGG 3660 GCAGAGATTG AAAATTATGT CTTGACCTAC AAATCCACCG ACGGAAGCCG CAAGGAGCTG 3720 ATTGTGGATG CAGAAGACAC CTGGATTCGA CTGGAGGGCC TGTTGGAGAA CACAGACTAC 3780 ACGGTGCTCC TGCAGGCAAC ACAGGACACC ACGTGGAGCA GCATCACCTC CACCGCTTTC 3840 ACCACAGGAG GCCGGGTGTT CCCTCATCCC CAAGACTGTG CCCAGCATTT GATGAATGGA 3900 GACACTTTGA GTGGGGTTTA CCCCATCTTC CTCAATGGGG AGCTGAGCCA GAAATTACAA 3960 GTGTACTGTG ATATGACCAC CGACGGGGGC GGCTGGATTG TATTCCAGAG GCGGCAGAAT 4020 GGCCAAACTG ATTTTTTCCG GAAATGGGCT GATTACCGTG TTGGCTTCGG GAACGTGGAG 4080 GATGAGTTCT GGCTGGGGCT GGACAATATA CACAGGATCA CATCCCAGGG CCGCTATGAG 4140 CTGCGCGTGG ACATGCGGGA TGGCCAGGAG GCCGCCTTCG CCTCCTACGA CAGGTTCTCT 4200 GTCGAGGACA GCAGAAACCT GTACAAACTC CGCATAGGAA GCTACAACGG CACTGCGGGG 4260 GACTCCCTCA GCTATCATCA AGGACGCCCT TTCTCCACAG AGGATAGAGA CAATGATGTT 4320 GCAGTGACTA ACTGTGCCAT GTCGTACAAG GGAGCATGGT GGTATAAGAA CTGCCACCGG 4380 ACCAACCTCA ATGGGAAGTA CGGGGAGTCC AGGCACAGTC AGGGCATCAA CTGGTACCAT 4440 TGGAAAGGCC ATGAGTTCTC CATCCCCTTT GTGGAAATGA AGATGCGCCC CTACAACCAC 4500 CGTCTCATGG CAGGGAGAAA ACGGCAGTCC TTACAGTTCT GAGCAGTGGG CGGCTGCAAG 4560 CCAACCAATA TTTTCTGTCA TTTGTTTGTA TTTTATAATA TGAAACAAGG GGGGAGGGTA 4620 ATAGCAATGT TTTTTGCAAC ATATTAAGAG TATGTNAAGG AAGCAGGGAT GTCGCAGGAA 4680 TCCGCTGGCT AACATCTGCT CTNGGTTTCT GCTGNCCTGG AGGC 4724 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1358 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4 12 JtfJBStl SIieøHllEZβ) Met Gly Ala Asp Gly Glu Thr Val Val Leu Lys Asn Met Leu lie Gly 1 5 10 15 Val Asn Leu lie Leu Leu Gly Ser Met lie Lys Pro Ser Glu Cys Gin 20 25 30 Leu Glu Val Thr Thr Glu Arg Val Gin Arg Gin Ser Val Glu Glu Glu 35 40 45 Gly Gly He Ala Asn Tyr Asn Thr Ser Ser Lys Glu Gin Pro Val Val 50 55 60 Phe Asn His Val Tyr Asn He Asn Val Pro Leu Asp Asn Leu Cys Ser 65 70 75 80 Ser Gly Leu Glu Ala Ser Ala Glu Gin Glu Val Ser Ala Glu Asp Glu 85 90 95 Thr Leu Ala Glu Tyr Met Gly Gin Thr Ser Asp His Glu Ser Gin Val 100 105 110 Thr Phe Thr His Arg He Asn Phe Pro Lyε Lys Ala Cys Pro Cys Ser 115 120 125 Ser Ser Ala Gin Val Leu Gin Glu Leu Leu Ser Arg He Glu Met Leu 130 135 140 Glu Arg Glu Val Ser Val Leu Arg Asp Gin Cys Asn Ala Asn Cys Cys 145 150 155 160 Gin Glu Ser Ala Ala Thr Gly Gin Leu Asp Tyr He Pro His Cys Ser 165 170 175 Gly His Gly Asn Phe Ser Phe Glu Ser Cys Gly Cys He Cys Asn Glu 180 185 190 Gly Trp Phe Gly Lys Asn Cys Ser Glu Pro Tyr Cys Pro Leu Gly Cys 195 200 205 Ser Ser Arg Gly Val Cys Val Asp Gly Gin Cys He Cys Asp Ser Glu 210 215 220 Tyr Ser Gly Asp Asp Cys Ser Glu Leu Arg Cys Pro Thr Asp Cys Ser 225 230 235 240 Ser Arg Gly Leu Cys Val Asp Gly Glu Cys Val Cys Glu Glu Pro Tyr 245 250 255 Thr Gly Glu Asp Cys Arg Glu Leu Arg Cys Pro Gly Asp Cys Ser Gly 260 265 270 Lys Gly Arg Cys Ala Thr Gly Thr Cys Leu Cys Glu Glu Gly Tyr Val 275 280 285 Gly Glu Asp Cys Gly Gin Arg Gin Cys Leu Asn Ala Cys Ser Gly Arg 290 295 300 Gly Gin Cys Glu Glu Gly Leu Cys Val Cys Glu Glu Gly Tyr Gin Gly 305 310 315 320 Pro Asp Cys Ser Ala Val Ala Pro Pro Glu Asp Leu Arg Val Ala Gly 325 330 335 He Ser Asp Arg Ser He Glu Leu Glu Trp Asp Gly Pro Met Ala Val SUBSTITUTE SHET (Will 26) 340 345 350 Thr Glu Tyr Val He Ser Tyr Gin Pro Thr Ala Leu Gly Gly Leu Gin 355 360 365 Leu Gin Gin Arg Val Pro Gly Asp Trp Ser Gly Val Thr He Thr Glu 370 375 380 Leu Glu Pro Gly Leu Thr Tyr Asn He Ser Val Tyr Ala Val He Ser 385 390 395 400 Asn He Leu Ser Leu Pro He Thr Ala Lys Val Ala Thr His Leu Ser 405 410 415 Thr Pro Gin Gly Leu Gin Phe Lys Thr He Thr Glu Thr Thr Val Glu 420 425 430 Val Gin Trp Glu Pro Phe Ser Phe Ser Phe Asp Gly Trp Glu He Ser 435 440 445 Phe He Pro Lys Asn Asn Glu Gly Gly Val He Ala Gin Val Pro Ser 450 455 460 Asp Val Thr Ser Phe Asn Gin Thr Gly Leu Lys Pro Gly Glu Glu Tyr 465 470 475 480 He Val Asn Val Val Ala Leu Lys Glu Gin Ala Arg Ser Pro Pro Thr 485 490 495 Ser Ala Ser Val Ser Thr Val He Asp Gly Pro Thr Gin He Leu Val 500 505 510 Arg Asp Val Ser Asp Thr Val Ala Phe Val Glu Trp He Pro Pro Arg 515 520 525 Ala Lys Val Asp Phe He Leu Leu Lys Tyr Gly Leu Val Gly Gly Glu 530 535 540 Gly Gly Arg Thr Thr Phe Arg Leu Gin Pro Pro Leu Ser Gin Tyr Ser 545 550 555 560 Val Gin Ala Leu Arg Pro Gly Ser Arg Tyr Glu Val Ser Val Ser Ala 565 570 575 Val Arg Gly Thr Asn Glu Ser Asp Ser Ala Thr Thr Gin Phe Thr Thr 580 585 590 Glu He Asp Ala Pro Lys Asn Leu Arg Val Gly Ser Arg Thr Ala Thr 595 600 605 Ser Leu Asp Leu Glu Trp Asp Asn Ser Glu Ala Glu Val Gin Glu Tyr 610 615 620 Lys Val Val Tyr Ser Thr Leu Ala Gly Glu Gin Tyr His Glu Val Leu 625 630 635 640 Val Pro Lys Gly He Gly Pro Thr Thr Arg Ala Thr Leu Thr Asp Leu 645 650 655 Val Pro Gly Thr Glu Tyr Gly Val Gly He Ser Ala Val Met Asn Ser 660 665 670 Gin Gin Ser Val Pro Ala Thr Met Asn Ala Arg Thr Glu Leu Asp Ser 675 680 685 14 SUBSTPT SHEET (RULE 26) Pro Arg Asp Leu Met Val Thr Ala Ser Ser Glu Thr Ser He Ser Leu 690 695 700 He Trp Thr Lys Ala Ser Gly Pro He Asp His Tyr Arg He Thr Phe 705 710 715 720 Thr Pro Ser Ser Gly He Ala Ser Glu Val Thr Val Pro Lys Asp Arg 725 730 735 Thr Ser Tyr Thr Leu Thr Asp Leu Glu Pro Gly Ala Glu Tyr He He 740 745 750 Ser Val Thr Ala Glu Arg Gly Arg Gin Gin Ser Leu Glu Ser Thr Val 755 760 765 Asp Ala Phe Thr Gly Phe Arg Pro He Ser His Leu His Phe Ser His 770 775 780 Val Thr Ser Ser Ser Val Asn He Thr Trp Ser Asp Pro Ser Pro Pro 785 790 795 800 Ala Asp Arg Leu He Leu Asn Tyr Ser Pro Arg Asp Glu Glu Glu Glu 805 810 815 Met Met Glu Val Ser Leu Asp Ala Thr Lys Arg His Ala Val Leu Met 820 825 830 Gly Leu Gin Pro Ala Thr Glu Tyr He Val Asn Leu Val Ala Val His 835 840 845 Gly Thr Val Thr Ser Glu Pro He Val Gly Ser He Thr Thr Gly He 850 855 860 Asp Pro Pro Lys Asp He Thr He Ser Asn Val Thr Lys Asp Ser Val 865 870 875 880 Met Val Ser Trp Ser Pro Pro Val Ala Ser Phe Asp Tyr Tyr Arg Val 885 890 895 Ser Tyr Arg Pro Thr Gin Val Gly Arg Leu Asp Ser Ser Val Val Pro 900 905 910 Asn Thr Val Thr Glu Phe Thr He Thr Arg Leu Asn Pro Ala Thr Glu 915 920 925 Tyr Glu He Ser Leu Asn Ser Val Arg Gly Arg Glu Glu Ser Glu Arg 930 935 940 He Cys Thr Leu Val His Thr Ala Met Asp Asn Pro Val Asp Leu He 945 950 955 960 Ala Thr Asn He Thr Pro Thr Glu Ala Leu Leu Gin Trp Lys Ala Pro 965 970 975 Val Gly Glu Val Glu Asn Tyr Val He Val Leu Thr His Phe Ala Val 980 985 990 Ala Gly Glu Thr He Leu Val Asp Gly Val Ser Glu Glu Phe Arg Leu 995 1000 1005 Val Asp Leu Leu Pro Ser Thr His Tyr Thr Ala Thr Met Tyr Ala Thr 1010 1015 1020 15 SUBSTTΠITE SHEET RDl£ 26 Asn Gly Pro Leu Thr Ser Gly Thr He Ser Thr Asn Phe Ser Thr Leu 1025 1030 1035 1040 Leu Asp Pro Pro Ala Asn Leu Thr Ala Ser Glu Val Thr Arg Gin Ser 1045 1050 1055 Ala Leu He Ser Trp Gin Pro Pro Arg Ala Glu He Glu Asn Tyr Val 1060 1065 1070 Leu Thr Tyr Lys Ser Thr Asp Gly Ser Arg Lys Glu Leu He Val Asp 1075 1080 1085 Ala Glu Asp Thr Trp He Arg Leu Glu Gly Leu Leu Glu Asn Thr Asp 1090 1095 1100 Tyr Thr Val Leu Leu Gin Ala Thr Gin Asp Thr Thr Trp Ser Ser He 1105 1110 1115 1120 Thr Ser Thr Ala Phe Thr Thr Gly Gly Arg Val Phe Pro His Pro Gin 1125 1130 1135 Asp Cys Ala Gin His Leu Met Asn Gly Asp Thr Leu Ser Gly Val Tyr 1140 1145 1150 Pro He Phe Leu Asn Gly Glu Leu Ser Gin Lys Leu Gin Val Tyr Cys 1155 1160 1165 Asp Met Thr Thr Asp Gly Gly Gly Trp He Val Phe Gin Arg Arg Gin 1170 1175 1180 Asn Gly Gin Thr Asp Phe Phe Arg Lys Trp Ala Asp Tyr Arg Val Gly 1185 1190 1195 1200 Phe Gly Asn Val Glu Asp Glu Phe Trp Leu Gly Leu Asp Asn He His 1205 1210 1215 Arg He Thr Ser Gin Gly Arg Tyr Glu Leu Arg Val Asp Met Arg Asp 1220 1225 1230 Gly Gin Glu Ala Ala Phe Ala Ser Tyr Asp Arg Phe Ser Val Glu Asp 1235 1240 1245 Ser Arg Asn Leu Tyr Lys Leu Arg He Gly Sei Tyr Asn Gly Thr Ala 1250 1255 1260 Gly Asp Ser Leu Ser Tyr His Gin Gly Arg Pro Phe Ser Thr Glu Asp 1265 1270 1275 1280 Arg Asp Asn Asp Val Ala Val Thr Asn Cys Ala Met Ser Tyr Lys Gly 1285 1290 1295 Ala Trp Trp Tyr Lys Asn Cys His Arg Thr Asn Leu Asn Gly Lys Tyr 1300 1305 1310 Gly Glu Ser Arg His Ser Gin Gly He Asn Trp Tyr His Trp Lys Gly 1315 1320 1325 His Glu Phe Ser He Pro Phe Val Glu Met Lys Met Arg Pro Tyr Asn 1330 1335 1340 His Arg Leu Met Ala Gly Arg Lys Arg Gin Ser Leu Gin Phe 1345 1350 1355 16 StlBSTTrϋTE SHEET R

Claims: WHAT IS CLAIMED IS: 1. A nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of SEQ ID NO.3, a complement of SEQ ID NO.3, a degenerate nucleotide sequence which encodes SEQ ID NO:4, and RNA equivalents thereof 2. A nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of nucleotides 2686-3165 of SEQ ID NO 3, a complement of nucleotides 2686- 3165 of SEQ ID NO 3, and RNA equivalents thereof 3 An expression vector comprising the nucleotide sequence of SEQ ID NO 3 or nucleotides 2686-3165 of SEQ ID NO 3 4. A host cell transformed or transfected with the expression vector of Claim 3 5. A method for detecting a nucleic acid sequence encoding human restrictin comprising detecting hybridization of a nucleic acid molecule selected from the group consisting of SEQ ID NO.3, nucleotides 2686-3165 of SEQ ID NO 3 and complements thereof to the nucleic acid sequence 6 A protein consisting of the amino acid sequence of SEQ ID NO 4 7 An anti-human restrictin antibody 8 The antibody of Claim 2 which is a polyclonal antibods 9 The antibody of Claim 2 which is a monoclonal antibody 10 A method for detecting restrictin comprising detecting binding of an anti-human restrictin antibody to the restrictin 1 1 The method of Claim 1 wherein the restrictin is detected in tissue 12 The method of Claim 1 wherein the restrictin is detected in a cell or tissue extract 17 T

Inventors: ACKLEY RHONDA LUCILLE, HEMPERLY JOHN JACOB, REID ROBERT ALAN, ACKLEY, RHONDA, LUCILLE, HEMPERLY, JOHN, JACOB, REID, ROBERT, ALAN
Applicants: BECTON DICKINSON CO, BECTON, DICKINSON AND COMPANY
Application year: 1996
Main classification: C12N15
IPC codes: A61K38, C07K14, C07K16, C12N1, C12N15, C12P21, C12Q1, C12R1, G01N33